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Being a highly prevalent disease, osteoporosis causes metabolism defects. Low bone
density, compromised bone strength, and an increased danger of fragility fracture
are its main characteristics. Natural compounds have been considered as potential
alternative therapeutic agents for treating osteoporosis. In this study, we demonstrated
that a natural compound, praeruptorin C (Pra-C), derived from the dried roots of
Peucedanum praeruptorum, has beneficial effects in suppressing osteoclast formation
and resorption function via attenuating the activation of nuclear factor kappa B as
well as c-Jun N-terminal kinase/mitogen-activated protein kinase signaling pathways.
Moreover, Pra-C was tested in the ovariectomized (OVX) mice, a well-established model
of post-menopausal bone loss, and the results indicated Pra-C exerted beneficial effects
on inhibiting excessive osteoclast activity and increasing bone mass of OVX mice.
Therefore, the protective effects of Pra-C on OVX mice bone are related to its inhibition
of osteoclast formation and bone resorption, suggesting that Pra-C is a good potential
candidate for osteoporosis treatment.
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INTRODUCTION
Bone is a tough and dynamic tissue. It can constantly change its mass as well as its shape to
provide the physiological strength needed for an organism’s structural framework. Osteoblasts,
osteocytes, and osteoclasts activate to maintain bone homeostasis in a restructuring process called
“bone remodeling” (Seeman and Delmas, 2006). Imbalances in the bone remodeling process lead
to skeletal diseases. Excessive osteoclastic activity contributes to pathological bone resorption that
accounts for most adult skeletal diseases (Rodan and Martin, 2000). Osteoporosis is an example
of excessive osteoclast activity (Kong et al., 1999, 2000; Holt et al., 2007), causing low bone
mass, compromised bone strength, and increased risk of fragility fracture. Considering this fact,
osteoclasts are a key target during the treatment of osteoclast-related osteolytic diseases (Phan et al.,
2004). Agents that modulate aberrant osteoclast formation and activity have the potential for use
as bone-protective therapies (Zhu et al., 2016).
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The monocyte/macrophage lineage is the main source of
osteoclasts (Udagawa et al., 1990). Two hematopoietic factors,
macrophage colony-stimulating factor (M-CSF) and the receptor
activator of nuclear factor kappa B ligand (RANKL), are
necessary for osteoclast proliferation and variation, respectively
(Lacey et al., 1998; Yao et al., 2002). The binding of RANKL on
its receptor, RANK, activates signaling pathways that ultimately
lead to osteoclastogenesis. The negative controller of this pathway
is osteoprotegerin, the soluble “decoy receptor” for RANKL
(Simonet et al., 1997; Lacey et al., 1998; Khosla, 2001). There
are at least four distinct signaling pathways activated by RANKL
that lead to osteoclastogenesis: nuclear factor kappa B (NF-κB),
c-Jun N-terminal kinase (JNK), p38, and extracellular signal-
regulated kinase (ERK) (Grigoriadis et al., 1994; Franzoso et al.,
1997; Wong et al., 1999; Matsumoto et al., 2000; Hotokezaka
et al., 2002; Boyle et al., 2003). On the basis of relevant knowledge
and existing outcomes, previous research has created and selected
new compounds that are able to inhibit osteoclast formation
and activation (Qin et al., 2012; Liu et al., 2014; Qu et al.,
2014).
Praeruptorin C (Pra-C) is derived from the dried roots of
Peucedanum praeruptorum (Peucedani Radix), a therapeutic
herb that is frequently utilized in traditional Chinese medicine
for treating upper respiratory infections and as an antipyretic,
antitussive, and mucolytic agent (Sarkhail et al., 2013).
Specifically, it has been shown that Pra-C plays an important role
in vascular smooth muscle relaxation (Zhao et al., 1999; Rao et al.,
2001), exhibits anti-inflammatory activity in lipopolysaccharide-
activated RAW264.7 murine macrophage cells by inhibiting
NF-κB and signal transducer and activator of transcription 3
(Yu et al., 2012), and has neuroprotective effects by inhibiting
neuronal apoptosis through down-regulation of GluN2B-
containing N-methyl-D-aspartate receptors (Yang et al., 2013).
Given its anti-inflammatory effect via inhibiting NF-κB, and
the importance of the NF-κB pathway in osteoclastogenesis
(Franzoso et al., 1997; Yu et al., 2012), we hypothesized that
Pra-C will provide therapeutic benefits for treating osteoclast-
related diseases. The two main aims of this research were to
investigate the underlying beneficial effects of Pra-C therapy in
a mouse model of osteoporosis and to ascertain the impact of
Pra-C on osteoclastogenesis.
MATERIALS AND METHODS
Reagents
RAW264.7 cells were purchased from the American Type
Culture Collection (ATCC, Rockville, MD, United States). The
alpha modification of minimum essential medium (α-MEM),
fetal bovine serum (FBS), and penicillin were acquired from
Gibco-BRL (Sydney, Australia). R&D Systems (Minneapolis,
MN, United States) provided recombinant soluble human
M-CSF and mouse RANKL. In addition, we acquired tartrate-
resistant acid phosphatase (TRAP)-staining kit and Pra-C
from Sigma-Aldrich (St. Louis, MO, United States) and
Meilun Corporation (Dalian, China), respectively; to meet
standard requirements, it was essential that the Pra-C was over
98% pure. We purchased antibodies against glyceraldehyde
3-phosphate dehydrogenase (GAPDH), phospho-IκBα,
IκBα, ERK, phospho-ERK, JNK, phospho-JNK, p38, and
phospho-p38 from Cell Signaling Technology (Cambridge, MA,
United States).
Cell Culture
As previously described (Li et al., 2013), bone marrow
monocyte/macrophage (BMM) cells were isolated from the
femurs and tibias of 4- to 6-week-old C57BL/6 mice and
were cultured in α-MEM containing 30 ng/mL M-CSF, 10%
heat-inactivated FBS, and 1% penicillin/streptomycin for 24 h.
Then, we separated the adherent cells from the non-adherent
cells. The adherent cells were cultivated in a 37◦C, 5% CO2
incubator until they were confluent. This process usually required
3–4 days. RAW264.7 cells were cultivated in α-MEM with
1% penicillin/streptomycin and 10% FBS at 37◦C in a 5%
CO2 incubator. To prepare BMMs and RAW264.7 cells for
experiments, the cells (approximately 90% confluent) were
washed three times with phosphate-buffered saline (PBS), and
were then trypsinized for approximately 3 min.
In Vitro Osteoclastogenesis Assay
We seeded BMM cells in a 96-well plate at a density of
8 × 103 cells/well in complete α-MEM with 50 ng/mL RANKL
and 30 ng/mL M-CSF added. The cells were treated with Pra-C
at different concentrations (0, 5, 10, or 20 µM). Every 2 days,
the medium was changed, which continued until the osteoclasts
matured in the control group. Next, the cells were fixed with
4% paraformaldehyde in PBS twice for approximately 20 min
each. Then, a Diagnostic Acid Phosphatase staining kit was
used to stain the cells for TRAP. Photographs of the TRAP+
multinucleated cells were taken. The percentage of TRAP+ cell
area in each well was measured and the number of TRAP+ cells
was determined. TRAP+ cells whose nuclei number was greater
than 3 were classified as osteoclasts.
Cell Viability Assay
To assess Pra-C’s cytotoxic effects, we used cell counting
kit-8 (CCK-8, Dojindo Molecular Technologies, Inc.,
Kumamoto, Japan), following the manufacturer’s protocol.
In vitro, mature osteoclasts are created by differentiating
monocytes/macrophages with M-CSF and RANKL. Using the
monocyte/macrophage, osteoclast precursors, we conducted an
experiment to assess cell viability with Pra-C treatment. Briefly,
BMMs were then added to 96-well plates at 8× 103 cells/well and
cultured for 24 h in complete α-MEM with 30 ng/mL M-CSF.
Cells were then treated with varying concentrations of Pra-C (0,
5, 10, 20, 40, 80, 160, or 320 µM) for 2 days. Afterward, 10 µL of
CCK-8 substrate was added to every well. The cells were cultured
in a 37◦C, 5% CO2 incubator for another 2 h. The absorbance
at 450 nm (650 nm reference) of each well was measured with
an ELX800 microplate reader (Bio-Tek, United States). The
following formula was used to calculate the cell viability relative
to that of the control cells: (experimental group OD − blank
OD)/(control group OD− blank OD).
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Cell Apoptosis Assay
We seeded BMM cells in a six-well plate at a density of
2× 105 cells/well. Different concentrations (0, 5, 10, or 20 µM) of
Pra-C were used to treat the cells for 48 h. After washing the cells
with cold PBS and collecting the cells by centrifugation, the cell
pellets were suspended in 1× annexin-binding buffer. The cell
death ratios were evaluated by Annexin V-APC and propidium
iodide staining (Becton-Dickinson Company, United States).
Purification of RNA and RT-qPCR
We used quantitative reverse transcription polymerase chain
reaction (RT-qPCR) to analyze gene expression during the
formation of osteoclasts. BMMs were seeded in a six-well plate at
a density of 1× 105 cells/well in complete α-MEM with 50 ng/mL
RANKL and 30 ng/mL M-CSF. We then treated the cells with
different concentrations of Pra-C (0, 10, or 20 µM) until mature
osteoclasts formed. The RNeasy Mini kit (Qiagen, Valencia,
CA, United States) was used to purify total RNA, following
manufacturer’s instructions. cDNA was synthesized from 1 µg
total RNA using reverse transcriptase (TaKaRa Biotechnology,
Otsu, Japan). Real-time PCR was then conducted with the
ABI 7500 Sequencing Detection System (Applied Biosystems,
Foster City, CA, United States) and the SYBR Premix Ex Taq
kit (TaKaRa). The cycling conditions were as follows: 40 cycles
of denaturation at 95◦C for 5 s and extension at 60◦C for 24 s
(Tian et al., 2014). All reactions were performed in triplicate.
GAPDH served as the normalizing gene. As depicted previously
(Liu et al., 2014), the mouse primer sequences for GAPDH,
TRAP, V-ATPase a3, V-ATPase d2, Cathepsin K (Ctsk), c-fos,
calcitonin receptor (CTR), dendritic cell-specific transmembrane
protein (DC-STAMP), and nuclear factor of activated T-cells
1 (NFATC1) are shown below: GAPDH forward 5′-ACCC
AGAAGACTGTGGATGG-3′ and reverse 5′-CACATTGGGGG
TAGGAACAC-3′, TRAP forward 5′-CTGGAGTGCACGA
TGCCAGCGACA-3′ and reverse 5′-TCCGTGCTCGGCGATG
GACCAGA-3′, V-ATPase a3 forward 5′-GCCTCAGGGGAA
GGCCAGATCG-3′ and reverse 5′-GGCCACCTCTTCACTCC
GGAA-3′, V-ATPase d2 forward 5′-AAGCCTTTGTTTGACG
CTGT-3′ and reverse 5′-TTCGATGCCTCTGTGAGATG-3′,
Ctsk forward 5′-CTTCCAATACGTGCAGCAGA-3′ and
reverse 5′-TCTTCAGGGCTTTCTCGTTC-3′, c-fos forward
5′-CCAGTCAAGAGCATCAGCAA-3′ and reverse 5′-AAG
TAGTGCAGCCCGGAGTA-3′, CTR forward 5′-TGCAGAC
AACTCTTGGTTGG-3′ and reverse 5′-TCGGTTTCTTCTCC
TCTGGA-3′, DC-STAMP forward 5′-AAAACCCTTGGGCT
GTTCTT-3′and reverse 5′-AATCATGGACGACTCCTTGG-3′,
NFATC1 forward 5′-CCGTTGCTTCCAGAAAATAACA-3′ and
reverse 5′-TGTGGGATGTGAACTCGGAA-3′.
Resorption Pit Assay
We placed bovine bone slices in a 96-well plate and then
seeded BMMs at 8 × 103 cells/well on top in complete
α-MEM containing 50 ng/mL RANKL and 30 ng/mL M-CSF.
Once mature osteoclasts had formed, we treated with varying
concentrations of Pra-C (0, 5, 10, or 20 µM) for another 48 h.
Then, with the assistance of mechanical agitation and sonication,
the cells adherent to the bone slices, were removed. A scanning
electron microscope (FEI Quanta 250) was used to visualize
the resorption pits. Image J software (National Institutes of
Health, Bethesda, MD, United States) was used to calculate the
absorbance areas of the bone slices.
F-Actin Ring Immunofluorescence
In order to observe the F-actin ring (the ruﬄed membrane
of an osteoclast) formation, we cultivated the BMM-derived
osteoclasts on bovine bone slices, and then treated them with
different Pra-C concentrations (0, 5, 10, or 20 µM) for 48 h.
Following that, we fixed the cells with 4% paraformaldehyde for
20 min. The cells were then permeabilized with 0.1% (v/v) Triton
X-100 (Sigma-Aldrich, St. Louis, MO, United States) for 5 min,
and incubated with Alexa Fluor 647 phalloidin (Invitrogen, San
Diego, CA, United States) for 1 h. The cells were washed with
PBS three times. The cell nuclei were then stained with Hoechst
3342 dye (1:5000; Invitrogen), washed with PBS, and mounted
on microscope slides with ProLong Gold anti-fade mounting
medium (Invitrogen). Fluorescent staining of the F-actin ring was
observed with a NIKON A1Si spectral detector confocal system
with 10× (dry) lenses equipped.
Western Blot Analysis
Western blot analysis was conducted according to previously
published protocols (Liu et al., 2014). RAW264.7 cells were
seeded in six-well plates at 5 × 105 cells/well. After reaching
confluence, the cells were pre-treated with or without 20 µM
Pra-C for 4 h, and then were stimulated with 50 ng/mL
RANKL for 0, 5, 10, 20, 30, or 60 min. Afterward, we
washed the cells with PBS and then lysed them using radio-
immunoprecipitation assay lysis buffer (50 mM Tris–HCl, 5 mM
EDTA, 150 mM NaCl, 1% Triton X-100, 1 mM sodium
vanadate, 1 mM sodium fluoride, 1% deoxycholate) with freshly
added phenylmethylsulfonyl fluoride (Tian Neng Bo Cai Corp,
Shanghai, China). We centrifuged the lysates at 12,000 g for
15 min, and collected the supernatants. A bicinchoninic acid
assay was used to determine the protein concentrations. As
previously reported (Tian et al., 2014), we separated 30 mg of
each protein lysate by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (10% gels). The proteins were transferred to
polyvinylidene difluoride membranes (Millipore, Bedford, MA,
United States). For membranes, they were blocked for 1 h using
5% skim milk powder in TBS-Tween (0.05 M Tris–HCl, pH 7.5,
0.15 M NaCl, and 0.2% Tween-20), and then incubated overnight
at 4◦C with primary antibodies diluted with 1% skim milk
powder in TBS-Tween. The next day, they were washed and then
incubated with the corresponding second antibody coupled with
IRDye 800CW (molecular weight 1162 Da). Immunoreactive
bands were visualized with an Odyssey infrared imaging system
(LI-COR, NE, United States).
Ovariectomized Mouse Model
We used an ovariectomized (OVX) mouse model to analyze the
protective effect of Pra-C on the resorption of bone in vivo. All
animal tests were conducted according to the guiding principles
of the Animal Care Committee of Nanchang University. In brief,
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20 C57BL/6 mice that were healthy and 8 weeks old (n = 20;
weight, 21.51± 0.87 g) were divided into four groups: non-OVX
control mice (sham), OVX mice not treated with drugs (vehicle),
OVX mice treated with 5 mg/kg Pra-C (low), and OVX mice
treated with 10 mg/kg Pra-C (high) groups. All the mice were
housed under controlled temperature (22–24◦C) and humidity
(50–60%), with a 12 h light/dark cycle and water and food ad
libitum. The ovaries of the mice were removed as previously
described (Moriwaki et al., 2014; Wang et al., 2015). Briefly, after
anesthesia with 10% chloral hydrate, retroperitoneal incisions
were made ventral to the erector spinae muscles just caudal
to the last rib. The ovary and associated fat were located and
exteriorized by gentle retraction. To remove the ovary, a 4-0
catgut ligature was placed around the cranial portion of the uterus
and uterine vessels. The skin incision was closed with one or
two non-absorbable sutures. The low and high concentration
mouse groups received intraperitoneal injections with either
5 or 10 mg/kg Pra-C, respectively, every 2 days. As a control,
the sham and vehicle groups were injected with 0.9% sodium
chloride. After 4 weeks, the mice were euthanized. Their tibias
were harvested, fixed in 4% paraformaldehyde for 48 h, washed
with PBS, and transferred into 70% ethyl alcohol for Micro-CT
scanning or histological study.
Micro CT Scanning
A high definition Micro-CT (µCT80, Scanco Medical,
Switzerland) was used to analyze the fixed tibias. We set
the scanning protocol at a 10 µm equidistant definition, 70 kV
and 70 µA X-ray energy settings, and a voxel size of 10 µm
in three-dimensional (3D) form. Following reconstruction, we
chose a region of interest (i.e., 200 slices below the aspect 0.1 mm
to the growth plates at the proximal tibia) for further trabecular
bone analysis. The volume of bone to tissue (BV/TV, %),
trabecular number (Tb.N, 1/mm), trabecular separation (Tb.Sp,
mm), and trabecular thickness (Tb.Th, mm) were determined to
investigate trabecular structure (Peng et al., 2013).
Histological and Histomorphometric
Study
Following Micro-CT scanning, the tibia samples were decalcified
in 10% EDTA with continuous shaking for 3 weeks. After
that, they were embedded in paraffin. Tissue sections were
prepared and stained with hematoxylin for 5 min and eosin
for 2 min at 22–24◦C. Other sections were subjected to TRAP
staining, according to the instructions provided with the kit.
The specimens were visualized, and pictures were taken with
a high resolution microscope. Additionally, an area 1 mm in
height and width, 0.5 mm below the growth plate and excluding
the cortical bone, was chosen to quantify and perform statistical
analyses using BioQuant software. The volume of bone, tissue,
and TRAP+ multinucleated osteoclasts was quantified in all of
the samples.
Data Analysis
Data from cell and animal experiments were presented
as the means ± standard deviations (SD). We conducted
data analysis with unpaired Student’s t-test and one-way
ANOVA using SPSS 13.0 software (SPSS Inc., United States).
The unpaired Student’s t-test was used when comparing
experiments consisting of two groups. And If more than
two groups are analyzed, one-way ANOVA with post hoc
multiple comparisons were used to determine if the groups are
statistically different. For these, the data were tested for normality
and homogeneity of variance in advance. Briefly, variance
was proved to be equal by Levene’s test, and then, pairwise
comparison was analyzed according to Student–Newman–Keuls
test (SNKq). We considered these differences significant at
P < 0.05.
RESULTS
Pra-C Inhibits Osteoclast Formation
In Vitro
First, we studied whether Pra-C has an influence on osteoclast
formation in vitro. To test this, BMMs were cultured with
M-CSF (30 ng/mL) and RANKL (50 ng/mL). BMMs were
then treated with varying concentrations of Pra-C (0, 5, 10, or
20 µM) until mature osteoclasts formed. As expected, many
TRAP+ multinucleated osteoclasts formed in the group treated
without Pra-C (Figure 1A). Interestingly, the BMMs treated with
Pra-C showed a significant, concentration-dependent decrease
in mature osteoclast formation (Figures 1A–C). The decrease
in mature osteoclast formation could have been caused by a
cytotoxic effect of Pra-C. To exclude this possibility, we tested
the cell apoptosis rate using flow cytometry. As shown in
Figure 1D, 1.04% of the cells were apoptotic without Pra-C
treatment. Treatment with Pra-C at 5, 10, and 20 µM produced
an apoptotic rate of 1.06, 1.09, and 1.16%, respectively. Further
quantitative analysis indicated that no significant difference in
apoptosis rate was observed even at the highest concentration
of 20 µM (Figure 1E). Furthermore, to evaluate the cytotoxicity
of Pra-C, a CCK-8 assay was performed, and no cytotoxic effect
was observed up to 40 µM (Figure 1F). Thus, Pra-C inhibits
osteoclast formation in vitro concentration-dependently with no
cytotoxic effect on the cells.
Pra-C Inhibits RANKL-Induced Gene
Expression
To explore Pra-C’s influence on the formation of osteoclasts in
more detail, the influence of Pra-C on RANKL-induced gene
expression was investigated. RANKL-stimulated differentiation
of osteoclasts is dependent on numerous signaling pathways,
which lead to the upregulation of the expression of particular
genes (Boyle et al., 2003). We used RT-qPCR to evaluate RANKL-
induced mRNA expression levels of the following osteoclast-
linked genes: TRAP, V-ATPase a3, V-ATPase d2, Ctsk, c-fos, CTR,
DC-STAMP, and NFATC1. Figure 2 shows that the upregulation
of all these genes was attenuated by Pra-C treatment. Consistent
with previous results, Pra-C also inhibited the upregulation of
these genes in a concentration-dependant manner, with the
exception of c-fos and CTR. These results confirm the inhibition
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FIGURE 1 | Praeruptorin C (Pra-C) inhibits osteoclast formation without cytotoxic and apoptotic effects. (A) Bone marrow-derived macrophages (BMMs) were
treated with different concentrations of Pra-C (0, 5, 10, or 20 µM), followed by 30 ng/mL M-CSF and 50 ng/mL RANKL for 5–7 days. Then, cells were fixed with 4%
paraformaldehyde and subjected to tartrate-resistant acid phosphatase (TRAP) staining. (B) Quantification of the area of TRAP+ cells. (C) Quantification of the
number of TRAP+ cells. (D) BMMs were seeded in six-well plates and treated with different concentrations of Pra-C (0, 5, 10, or 20 µM) for another 48 h, and then
subjected to staining with Annexin V-APC and propidium iodide. Cells were analyzed by flow cytometry. (E) Quantification of the cell apoptosis rate by flow
cytometry. (F) BMMs were cultured in a 96-well plate and treated with 30 ng/mL M-CSF, and different concentrations of Pra-C, for 48 h. Cell viability was measured
by CCK-8 assay. All plotted data are the means ± SD (n = 3). ∗P < 0.05; ∗∗P < 0.01, versus 0 µM Pra-C.
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FIGURE 2 | Pra-C suppresses RANKL-induced osteoclast-specific gene expression. BMMs were seeded in six-well plates, and then stimulated with 30 ng/mL
M-CSF, 50 ng/mL RANKL, and 10 or 20 µM Pra-C. Once mature osteoclasts were observed, total RNA was extracted and the expression of osteoclast-specific
mRNA [(A) TRAP, (B) V-ATPase a3, (C) V-ATPase d2, (D) Cathepsin K, (E) c-fos, (F) calcitonin receptor, (G) DC-STAMP, and (H) NFATC1] was measured using
quantitative reverse transcription polymerase chain reaction. All experiments were performed at least three times. All plotted data are the means ± SD. ∗P < 0.05;
∗∗P < 0.01, versus 0 µM Pra-C.
of osteoclastogenesis by Pra-C by suppressing osteoclast-specific
gene expression in vitro.
Pra-C Attenuates Osteoclast Function
In Vitro
For an effective osteoclast function, formation of a highly
polarized F-actin ring is indispensable (Wilson et al., 2009).
Hence, we explored the influence of Pra-C on F-actin ring
formation. For the untreated control group, we observed a typical
F-actin ring using Alexa Fluor 647 Phalloidin and confocal
microscopy (Figure 3A). In the groups treated with varying
concentrations of Pra-C (5, 10, or 20 µM), Pra-C severely
affected F-actin ring formation and morphology. It was observed
that F-actin formation was suppressed in a concentration-
dependant manner, similar to that observed with the other assays
(Figures 3A,B).
Our previous results indicated that Pra-C inhibits the
formation of osteoclasts in vitro. Therefore, we hypothesized that
Pra-C would also attenuate osteoclast function in vitro. To test
this, we seeded BMMs onto bovine bone slices and stimulated
them with M-CSF and RANKL. Once mature osteoclasts formed,
they were treated with varying concentrations of Pra-C (0, 5,
10, or 20 µM) for 48 h. The bone slices were then analyzed
with a scanning electron microscope. Figure 3C shows many
bone resorption pits in the control group, while the quantity
of bone resorption pits is lower in the Pra-C-treated groups.
As shown in Figure 3D, there is a large bone resorption area
(∼70%) on the bone slice surface in the control group. However,
the resorption area significantly reduced to ∼40 and ∼10%
with Pra-C concentrations of 5 and 10 µM, respectively. We
observed almost no resorption pits when BMMs were treated
with a concentration of 20 µM Pra-C. These results show that
both osteoclast formation and osteoclast function are inhibited
by Pra-C in vitro.
Pra-C Suppresses RANKL-Induced
Activation of NF-κB and JNK Signaling
Pathways
To analyze potential mechanisms of inhibitory influence of Pra-C
on the formation of osteoclasts and their functions in vitro,
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FIGURE 3 | Pra-C impairs F-actin ring formation and inhibits osteoclast bone resorption function. (A) BMM-derived osteoclasts were cultured on bovine bone slices
and treated with M-CSF (30 ng/mL), RANKL (50 ng/mL), and the indicated concentrations of Pra-C (0, 5, 10, or 20 µM) for another 48 h. Cells were then fixed and
stained for F-actin ring formation with Alexa-Fluor 647 phalloidin (red) and imaged on a NIKON confocal system. Representative images are shown. Characteristic
F-actin rings were formed in untreated groups. When treated with Pra-C, the formation was suppressed in a concentration-dependent manner. (B) Quantification of
F-actin ring count using Image J software. (C) BMM-derived osteoclasts were cultured on bovine bone slices to conduct a pit resorption assay. Representative SEM
images are shown. When subjected to an SEM scanning of bone slices, vast resorption pits were observed in the control group, but they were significantly
decreased after treatment with Pra-C. The inhibitory effect occurred in a concentration-dependant manner. The white arrowheads represent resorption pits on bone
slices. (D) The percentage of absorbance area of bone slices was quantified using Image J software and plotted. All experiments were performed at least three
times. All plotted data are the means ± SD. Significant differences were determined using SNKq test. ∗P < 0.05; ∗∗P < 0.01, versus 0 µM Pra-C.
RANKL-induced signaling cascades were explored using western
blotting. The binding of RANKL to its receptor, RANK, activates
NF-κB and MAPKs (Nakashima et al., 2012). Activating the NF-
κB pathway is crucial for osteoclast formation. Furthermore,
the three major MAPK signaling cascades (p38, ERK, and
JNK) have also been shown to be crucial for inducing and
activating osteoclast formation and function. As expected after
RANKL stimulation, IκBα in the control group is rapidly
degraded within minutes. In comparison, IκBα degradation was
greatly impaired in the presence of Pra-C (Figures 4A,B). This
implies a disruption in the NF-κB pathway during osteoclast
formation. JNK phosphorylation also seemed to be inhibited, and
quantitative analysis indicated a significantly decreased phospho-
JNK signal after treatment with Pra-C, compared to that of the
control group (Figures 4A,D). This suggests that Pra-C also
inhibits the JNK signaling pathway during osteoclast formation.
The two remaining MAPK cascades (ERK and p38) showed no
difference in phosphorylation between the control group and the
Pra-C-treated group (Figures 4C,E,F). These results indicate that
Pra-C attenuates osteoclast formation by inhibiting NF-κB and
JNK pathways without influencing ERK and p38 pathways.
Pra-C Suppresses Bone Loss in OVX
Mice
After examining the influence of Pra-C on osteoclasts in vitro,
we investigated the influence of Pra-C on preventing bone loss
in vivo using an OVX mouse model. In Figure 5A, Micro-CT
with 3D reconstruction of the tibia shows obvious bone loss in
the vehicle group (vehicle-treated OVX mice). There is also more
trabecular bone in the group treated with a high concentration
of Pra-C (10 mg/kg) compared to that in the group treated
with a low concentration of Pra-C (5 mg/kg). Furthermore,
Figures 5B–E shows the histomorphometric analyses that were
performed to determine BV/TV (%), Tb.N (1/mm), Tb.Sp (mm),
and Tb.Th (mm). Compared to that of the sham group, all four
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FIGURE 4 | Pra-C impairs RANKL-induced NF-κB and JNK signaling pathways. (A) Total protein extracted from RAW264.7 cells that had been cultured with or
without 20 µM Pra-C for 4 h, followed by 50 ng/mL RANKL for the indicated times was subjected to western blotting with specific antibodies against IκBα,
phospho-JNK, JNK, and GAPDH. In the control group, IκBα rapidly degrades, and JNK is rapidly phosphorylated within 10 min. IκBα degradation and JNK
phosphorylation were greatly impaired in the presence of Pra-C. (B) The band intensities corresponding to IκBα were quantified and normalized to GAPDH levels
using Image J software, and are plotted. (C) Western blotting was used to analyze phospho-ERK, ERK, phospho-p38, and p38. No difference was observed in the
phosphorylation of these two cascades between the control and Pra-C-treated groups. (D) JNK phosphorylation was quantified and normalized to GAPDH levels,
and significant differences were shown between the control and Pra-C-treated groups. No significant differences were found when ERK phosphorylation (E) and p38
phosphorylation (F) were quantified. Values are expressed as means ± SD (∗P < 0.05; ∗∗P < 0.01 compared to control group). All the experiments were performed
at least three times and representative blots are shown in panels (A,C).
parameters revealed significantly more bone resorption in vehicle
group (P < 0.01). Moreover, BV/TV, Tb.N, and Tb.Th were
obviously higher in the Pra-C-injected groups than in the vehicle
group, while Tb.Sp was remarkably lower in the Pra-C-injected
groups than in the vehicle group. Additionally, when comparing
to the sham group, BV/TV and Tb.N was still lower in the two
Pra-C-treated groups, and a significant difference was observed
(P < 0.05). Otherwise, referring to Tb.Th and Tb.Sp, no obvious
difference was represented between sham and two Pra-C-treated
groups (P > 0.05). Based on these results, it is concluded that
Pra-C can partially prevent OVX-induced bone loss.
Further histological and histomorphometric analyses
confirmed the protective effect of Pra-C on preventing
bone loss. An increased mature osteoclast number was
observed in the vehicle-treated OVX group, leading to
significant bone loss and impaired trabecular microarchitecture
(Figure 6A). Compared to that of the OVX group, Pra-C-
treated groups showed a preservation of bone mass and
decreased mature osteoclast numbers (Figures 6B,C).
Quantitative analysis of histomorphometric vectors and
BV/TV showed similar results as the Micro-CT scanning did
(Figure 6B).
DISCUSSION
Bone homeostasis is maintained by two coordinated procedures,
osteoblast bone formation and osteoclast bone absorption (Boyle
et al., 2003; Teitelbaum and Ross, 2003; Horne et al., 2005). When
this balance is disturbed, increases or decreases in bone mass
will occur, and bone structure is altered. Osteoclasts, as the only
cells capable of degrading bone matrix, play a critical role in this
metabolic process. Perturbations, such as osteoporosis, primary
and secondary bone tumors, aseptic loosening of arthroplasty,
and rheumatoid arthritis, are all caused by over-activation of
osteoclasts and the resulting excessive bone destruction (Zaidi,
2007). Because of this, osteoclasts are considered a key target in
treating osteoclast-related osteolytic diseases (Phan et al., 2004).
One disease related to osteoclasts, osteoporosis, is becoming
a global health concern that causes huge medical, economic,
and social burdens. Treatments for osteoporosis currently focus
on two different classes of medication, antiresorptive agents
and anabolic agents (Amugongo et al., 2014). Approved and
recommended antiresorptive agents include bisphosphonates,
selective estrogen receptor modulators, and monoclonal
antibodies against RANKL (Denosumab). Although bone
turnover is decreased and bone microarchitecture is modified
using these antiresorptive agents, they are far from ideal because
of their side effects. Treatment with selective estrogen receptor
modulators may increase the risk of stroke and cardiovascular
events (Barrett-Connor et al., 2006), while prolonged use of
bisphosphonates has been associated with severe gastrointestinal
discomfort, atypical femoral fracture, and osteonecrosis of
the jaw (Fleisch, 2003; Yarom et al., 2007; Lenart et al., 2008;
Abrahamsen et al., 2009). Denosumab, a humanized monoclonal
antibody of RANKL, shows potent inhibitory effects on bone
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FIGURE 5 | Pra-C prevents ovariectomized (OVX) mouse bone loss. (A) Right tibias of all mice were harvested and subjected to a high-resolution Micro-CT
scanning. Representative three-dimensional (3D) reconstructed images are shown. Severe bone loss was observed in vehicle-treated OVX mice. Compared to that
of the vehicle-treated group, bone mass was increased in both Pra-C-treated groups. (B–E) Bone volume to tissue volume (BV/TV, %), trabecular number (Tb.N,
1/mm), trabecular thickness (Tb.Th, mm), and the trabecular separation (Tb.Sp, mm) of each sample were measured and analyzed. All plotted data are the
means ± SE (n = 5). ∗P < 0.05; ∗∗P < 0.01 compared to vehicle group.
resorption and rapid improvement of bone mineral density.
However, osteonecrosis of the jaw has been observed in
registration trials (six cases in 4450 patients) (Bone et al., 2013),
and its long-term efficacy remains to be confirmed. Teriparatide
(recombinant human parathyroid hormone), an anabolic agent
for osteoporosis, produces the largest increase in bone mineral
density, when compared to that of any other osteoporosis
treatment (Neer et al., 2001). However, its high cost and
inconvenient daily injections limit its usefulness to only severe
osteoporosis patients. Romosozumab, a humanized monoclonal
antibody, is associated with bone formation, increased bone
mineral density, and suppressed bone resorption, which is
different from any other anabolic agent (McClung et al., 2014;
Ishibashi et al., 2017). The novel effects of Romosozumab make
it a promising agent in treating osteoporosis (Clarke, 2014), but
its efficacy and safety still need to be evaluated in a Phase III
study. Considering the current therapeutic options, exploring
available agents to treat osteoporosis is an urgent clinical and
social requirement.
Natural compounds are potential alternative therapeutic
agents for treating osteoporosis. Many investigators have focused
on these compounds because their various bioactivities can
be useful in treating human diseases. Several natural herbs,
including icaritin, maslinic acid, and lycorine, show anti-
osteoporosis properties (Li et al., 2011; Peng et al., 2013; Chen
et al., 2015). In our research, we demonstrated that Pra-C,
which is derived from the dried roots of P. praeruptorum,
showed beneficial effects in preventing bone loss via suppression
of osteoclast formation and resorption activity. According to
previous findings, praeruptorins (A–D) have been adopted
in traditional Chinese medicine to treat cough and upper
respiratory infections, because of their antipyretic, antitussive,
and mucolytic properties (Xiong et al., 2012; Sarkhail, 2014).
Additionally, Pra-C exhibits anti-inflammatory activity and
neuroprotective effects due to the suppression of NF-κB signaling
and the down-regulation of GluN2B-containing N-methyl-D-
aspartate receptors (Yu et al., 2012; Yang et al., 2013). Given
the suppression of NF-κB cascades and their importance in
Frontiers in Pharmacology | www.frontiersin.org 9 September 2017 | Volume 8 | Article 627
fphar-08-00627 September 8, 2017 Time: 16:12 # 10
Liu et al. Praeruptorin C Inhibits Osteoclast Activity
FIGURE 6 | Pra-C prevents ovariectomized (OVX) mouse bone loss as
assessed with histological and histomorphometric analyses. (A) Decalcified
bone tissue was paraffin-embedded and sectioned for hematoxylin and eosin,
as well as tartrate-resistant acid phosphatase (TRAP) staining. Representative
microscopic images are shown at the indicated magnification. Increased bone
loss and TRAP-positive osteoclasts were observed in vehicle-treated OVX
mice, whereas Pra-C treatment reversed the pathology, bone loss, and the
number of mature osteoclasts was obviously reduced. The black arrowheads
represent TRAP-positive osteoclasts observed on the surface of trabecular
bone below growth plate. (B) Bone volume to tissue volume (BV/TV) and (C)
the number of TRAP-positive mature osteoclasts was counted in each sample
using BioQuant software. All plotted data are the means ± SE (n = 5).
∗P < 0.05; ∗∗P < 0.01 versus vehicle group.
osteoclast formation, we hypothesized that Pra-C would possess
an additional property of inhibiting osteoclast differentiation via
this mechanism. Thus, we focused our attention on the potential
influence of Pra-C on osteoclast formation, function, and the
therapeutic effect toward osteoclast-related diseases.
In this study, we clarified for the first time that Pra-C
suppresses osteoclastogenesis concentration-dependently, using
concentrations from 5 to 20 µM, without showing cytotoxicity
or apoptosis. Furthermore, osteoclast-specific gene expression,
including TRAP, V-ATPase a3, V-ATPase d2, Ctsk, c-fos, CTR,
DC-STAMP, and NFATC1, were also down-regulated after
treatment with Pra-C. The mature, multinucleated osteoclast cell
body is polarized, and it undergoes internal structural changes,
such as actin cytoskeleton rearrangements, during differentiation
(Boyle et al., 2003). A notable feature of polarized osteoclasts
is a ruﬄed membrane (also called the F-actin ring), which
contains numerous vacuolar proton pumps (H+-V-ATPase), and
is associated with osteoclast bone absorption activity (Boyle
et al., 2003; Teitelbaum and Ross, 2003). With the aim of
evaluating the effect of Pra-C on osteoclast resorption function,
F-actin immunofluorescence and bone resorption assays were
conducted. The results indicated that Pra-C impairs F-actin
formation and induces a generalized cytoskeletal membrane
disruption. Because of the inhibition of osteoclast differentiation
and disruption of the F-actin ring, the quantity and area of bone
absorption pits were radically reduced with the treated cells.
Regarding the mechanism underlying Pra-C’s effect on osteoclast
resorptive function, we hypothesize that the down-regulation of
NFATC1 expression impairs cytoskeletal membrane integrity and
formation of F-actin, resulting from the inhibition of integrin
αvβ3 and c-Src tyrosine kinase, both of which are downstream
of NFATC1 activation (Miyazaki et al., 2004; Crotti et al., 2006;
Nakamura et al., 2007). However, the precise mechanisms of the
pathways remain to be revealed in future investigations.
During the procedures of osteoclast differentiation, RANKL
binding to its receptor, RANK, on osteoclast precursor cells
triggers a rapid activation of several critical signaling cascades,
including NF-κB, JNK, ERK, and p38, due to recruitment
of the adaptor protein, TRAF6 (Nakashima et al., 2012;
Ouyang et al., 2014). As a result of these activated pathways,
extracellular stimuli are transmitted from the cell surface to the
nucleus. Former investigators have implicated p38-regulated
microphthalmia-associated transcription factor (Matsumoto
et al., 2000), ERK-induced activation of c-fos (Monje et al.,
2005), and JNK phosphorylated down-stream factors, including
c-fos and c-Jun, which combine to form the activator protein-1
(AP-1) heterodimer (Grigoriadis et al., 1994; Kobayashi
et al., 2001). Additionally, IκB degradation after IκB kinase
(IKK) phosphorylation is another important event during
osteoclastogenesis, resulting in NF-κB P65/RelA translocation
to the nucleus. Consistent with previous reports, our study
clearly indicated that the NF-κB pathway was suppressed by
Pra-C, and confirmed by the observation that IκB degradation
was significantly attenuated. Unexpectedly, the results showed
that the RANKL-induced JNK cascade was also impaired after
treatment with Pra-C. Therefore, related to the attenuation of
NF-κB and JNK cascades, disrupted osteoclast formation was
observed during the differentiation procedures when the BMMs
were induced with RANKL.
Pra-C’s suppressive effect on osteoclastogenesis and bone
resorption in vitro suggests that it is possible to use Pra-
C as an antiresorptive agent for treating osteolytic disease.
Osteoporosis is one of the most prevalent diseases resulting
from estrogen deficiency and the resulting over-activation of
osteoclasts. Therefore, we further studied the effect of Pra-
C in vivo using a model of post-menopausal bone loss.
Tibias separated from the mice were subjected to Micro-
CT scanning, hematoxylin and eosin staining, and osteoclast-
specific TRAP staining. Our results suggest that Pra-C is
beneficial for preventing bone loss and improving trabecular
bone microarchitecture by suppressing osteoclast formation.
In conclusion, this research demonstrated that Pra-C has a
beneficial effect on the bone of OVX mice, resulting from
inhibition of osteoclast formation and bone resorption. Our
research also indicated that this inhibitory effect was at
least partly due to the inhibition of RANKL-induced NF-κB
activation, as well as JNK signaling pathways. Therefore, Pra-C’s
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anti-resorptive properties make it good potential candidate for
osteoporosis treatment. However, further researches are still
required before it can be developed as a therapeutic agent.
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